Anzeige
Mehr »
Samstag, 11.04.2026 - Börsentäglich über 12.000 News
0,01% von 1 BILLIONEN USD = 100 MILLIONEN USD - Und UberDoc ist gerade erst an die Börse gegangen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Investing.com

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrSnap subsidiary signs multi-year Qualcomm chip deal for AR glasses
FrUFC signs Supersure as small business insurance partner
FrMilestone Pharmaceuticals plans real-world PSVT registry study
FrLiveOne partners with Team Boxing League for global streaming
FrErayak pivots to U.S.-focused energy solutions brand
FrBaird reiterates Neutral rating on Affirm stock amid macro concerns
FrBaird reiterates Neutral rating on BlackBerry stock at $5 target
FrWrap Technologies receives UK pre-order for 20 counter-drone systems
FrCoreWeave partners with Anthropic for AI model deployment
FrNeedham raises Constellation Brands stock price target on demand outlook
FrMizuho raises Alphabet stock price target on cloud growth outlook
FrMizuho raises Alkermes stock price target to $53 on drug confidence
FrMizuho reiterates Oracle stock rating on AI infrastructure edge
FrCanaccord lowers BlackBerry stock price target on valuation
FrH.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy
FrB.Riley upgrades MacroGenics stock rating on ADAM9 ADC potential
FrGuggenheim raises Zentalis stock price target on ovarian cancer drug data
FrExpedia stock seen best positioned for U.S. growth by BofA
FrGuggenheim raises Abbvie stock price target to $249 on immunology
FrCPP Group explores sale of Blink unit, seeks new funding
FrBeneficient closes $8.75M funding deal with Quartus AI Fund
FrH.C. Wainwright reiterates Zentalis stock rating on pivotal dose selection
FrH.C. Wainwright reiterates Kymera Therapeutics stock rating at buy
FrH.C. Wainwright reiterates Oncolytics Biotech stock rating at buy
FrH.C. Wainwright reiterates Nurix stock rating, $32 target on catalysts